(MedPage Today) — Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic cholangiocarcinoma [EHC] and…

Read the full article on medpagetoday.com